Icure Pharmaceutical Incorporation

아이큐어 · 175250

Materials Chemicals · KOSDAQ

Small-cap

Market cap US$59.1M (₩81.5B)

Overview

Icure Pharmaceutical makes medicated skin patches, adhesive drug-delivery systems worn on the body, as well as skincare and sheet-mask products manufactured under contract for other brands.

It supplies pharmaceutical customers and cosmetics companies, and is listed on KOSDAQ, South Korea's tech and small-cap exchange. The large majority of its revenue comes from the cosmetics contract-manufacturing business, while its pharmaceutical segment is anchored by a patch-form treatment for Alzheimer's disease.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$60.4M

▲ +20.5% YoY

Operating profit · FY2025

−US$8.7M

Loss narrowed

Net income · FY2025

−US$25M

Turned to loss

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$41.2M(₩56.8B)	US$50.2M(₩69.2B)	US$60.4M(₩83.4B)
Operating profit	−US$16.4M(−₩22.7B)	−US$12.5M(−₩17.2B)	−US$8.7M(−₩12B)
Net income	−US$23.4M(−₩32.3B)	US$17.9K(₩24.7M)	−US$25M(−₩34.5B)

Revenue

FY2023US$41.2M
FY2024US$50.2M
FY2025US$60.4M

Operating profit

FY2023−US$16.4M
FY2024−US$12.5M
FY2025−US$8.7M

Net income

FY2023−US$23.4M
FY2024US$17.9K
FY2025−US$25M

Key ratios (FY2025)

ROE

-141.1%

Debt/Eq

270.0%

Op. margin

-14.3%

Net margin

-41.4%

Rev. YoY

▲ +20.5%

Why it matters

The company has signed overseas licensing and supply agreements for its Alzheimer's patch with Menarini and Celltrion, both named in its filing.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?